HedgehogIN-11 is an orally active Hedgehog inhibitor. It reduces resistance to Temozolomide (TMZ) by downregulating O6-methylguanine-deoxyribonucleotides methyltransferase (MGMT) expression through the Hedgehog pathway. HedgehogIN-11 significantly inhibits the migration and invasion of TMZ-resistant glioblastoma cells and induces apoptosis. Computational modeling predicts good blood-brain barrier penetration for HedgehogIN-11. This compound is applicable for glioblastoma (GBM) research.
